Abstract
Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive/HER2-negative breast cancer (ER+/HER2-BC) allows real-time evaluation of drug efficacy and biological changes upon estrogenic deprivation. Clinical and pathological evaluation after NET may be used to obtain prognostic and predictive information of tumour response. Scales developed to evaluate response after neoadjuvant chemotherapy are not useful and there are not many validated biomarkers to assess response to NET. In this prospective study, we analysed radiological and pathological tumour response of 104 postmenopausal ER+/HER2-BC patients, treated with NET for a mean of 7 months. Our results show that radiological evaluation underestimates pathological tumour size, although it can be used to assess tumour response. In addition, we propose that the tumour cellularity size (TCS), calculated as the product of the residual tumour cellularity in the surgical specimen and the tumour pathological size, could become a new tool to standardize response assessment to NET. It is simple, reproducible and correlates with the existing biomarkers. Our findings shed light on the dynamics of NET response, challenge the paradigm of the ability of NET to decrease surgical volume and point to the utility of the TCS to quantify the scattered tumour response usually produced by endocrine therapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Spanish Ministry of Science and Innovation ISCIII (P20/01253, CP18/00076 and FI19/00193) and European Regional Development (FEDER) funds, Basque Department of Health (2020111040), Fundacion SEOM (SEOM Avon Fellowship 2020) and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patients charity Katxalin and from Roche Farma S.A. JILV is funded by an AECC PhD Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Spain Health Authority and Diputacion de Gipuzkoa gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* These authors share first authorship.
↵#These authors share senior and corresponding authorship.
Conflict of interest: The authors have declared that no conflict of interest exists.
There are not significant differences between this version and the previous version uploaded. Only misprints and text/figures formats have been modified.
Data availability statement
The data for this study are available upon reasonable request.
